PT3310331T - Formulações farmacêuticas injetáveis de lefamulina - Google Patents

Formulações farmacêuticas injetáveis de lefamulina

Info

Publication number: PT3310331T
Authority: PT; Portugal
Prior art keywords: lefamulin; pharmaceutical formulations; injectable pharmaceutical; injectable; formulations
Prior art date: 2015-06-17

Application number

PT167292580T

Other languages

English (en)

Original Assignee

Nabriva Therapeutics GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-17

Filing date

2016-06-14

Publication date

2021-01-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56131530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3310331(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-06-14 Application filed by Nabriva Therapeutics GmbH filed Critical Nabriva Therapeutics GmbH

2021-01-19 Publication of PT3310331T publication Critical patent/PT3310331T/pt

Links

KPVIXBKIJXZQJX-FCEONZPQSA-N 21904a5386 Chemical compound O([C@H]1[C@@]2(C)[C@@H]3C(=O)CC[C@]3([C@H]([C@H](O)[C@](C)(C=C)C1)C)CC[C@H]2C)C(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O KPVIXBKIJXZQJX-FCEONZPQSA-N 0.000 title 1
229950010255 lefamulin Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT167292580T 2015-06-17 2016-06-14 Formulações farmacêuticas injetáveis de lefamulina PT3310331T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562180871P	2015-06-17	2015-06-17

Publications (1)

Publication Number	Publication Date
PT3310331T true PT3310331T (pt)	2021-01-19

Family

ID=56131530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT167292580T PT3310331T (pt)	2015-06-17	2016-06-14	Formulações farmacêuticas injetáveis de lefamulina

Country Status (26)

Country	Link
US (2)	US12121582B2 (pt)
EP (1)	EP3310331B1 (pt)
JP (1)	JP6818019B2 (pt)
KR (1)	KR102656841B1 (pt)
CN (1)	CN107810000B (pt)
AU (1)	AU2016278774C1 (pt)
BR (1)	BR112017026904B1 (pt)
CA (1)	CA2989372C (pt)
CY (1)	CY1123722T1 (pt)
DK (1)	DK3310331T3 (pt)
EA (1)	EA033988B1 (pt)
ES (1)	ES2843723T3 (pt)
HR (1)	HRP20210010T1 (pt)
HU (1)	HUE053024T2 (pt)
IL (1)	IL256115A (pt)
LT (1)	LT3310331T (pt)
MX (1)	MX383032B (pt)
PH (1)	PH12017502319A1 (pt)
PL (1)	PL3310331T3 (pt)
PT (1)	PT3310331T (pt)
RS (1)	RS61327B1 (pt)
SI (1)	SI3310331T1 (pt)
TW (1)	TWI718158B (pt)
UA (1)	UA121240C2 (pt)
WO (1)	WO2016202788A1 (pt)
ZA (1)	ZA201707998B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN115397407A (zh)	2020-04-17	2022-11-25	纳布里瓦治疗有限责任公司	截短侧耳素类化合物的新治疗用途
US20230174472A1 (en)	2020-04-17	2023-06-08	Nabriva Therapeutics GmbH	Therapeutic use of pleuromutilins
US12630524B2 (en)	2020-04-17	2026-05-19	Ariva Med Gmbh	Pleuromutilin in derivatives for treating viral infections
EP4373960A4 (en) *	2021-07-19	2025-10-22	Jbs Science Inc	METHODS FOR ISOLATING CIRCULATING NUCLEIC ACIDS FROM URINE SAMPLES
EP4475834A1 (en)	2022-02-09	2024-12-18	Nabriva Therapeutics GMBH	Lefamulin and its derivatives for use in the treatment of a spiral shaped bacteria
EP4338732A1 (en)	2022-09-16	2024-03-20	Nabriva Therapeutics GMBH	Lefamulin and its derivatives for use in the treatment of tularemia

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4130709A (en)	1977-12-08	1978-12-19	Eli Lilly And Company	Pleuromutilin glycoside derivatives
JPS5910510A (ja) *	1982-07-08	1984-01-20	Nippon Zenyaku Kogyo Kk	低刺激性チアムリン注射剤
GB2228412B (en) *	1989-02-28	1993-04-14	Syntex Inc	Nicardipine pharmaceutical composition for parenteral administration
DE4023848C2 (de)	1990-07-27	1994-04-21	Huels Chemische Werke Ag	Verfahren zur Herstellung von 3-C¶1¶- bis C¶6¶-Alkoxycarbonylcyclohexanpropionsäureestern
FR2772272B1 (fr)	1997-12-16	2000-01-14	Rhone Poulenc Rorer Sa	Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
US6187746B1 (en)	1997-12-16	2001-02-13	Rhone-Poulenc Rorer S.A.	Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof
HUP0300370A3 (en)	2000-04-04	2005-07-28	Smithkline Beecham Plc	2-hydroxy-mutilin carbamate derivatives of antibacterial effect process for preparation and pharmaceutical compositions containing them
GB0017031D0 (en)	2000-07-11	2000-08-30	Biochemie Gmbh	Antimicrobials
GB0207495D0 (en)	2002-03-28	2002-05-08	Biochemie Gmbh	Organic compounds
GB0209262D0 (en)	2002-04-23	2002-06-05	Biochemie Gmbh	Organic compounds
GB0308114D0 (en) *	2003-04-08	2003-05-14	Glaxo Group Ltd	Novel compounds
MX2007008008A (es) *	2004-12-30	2007-11-12	Astex Therapeutics Ltd	Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
EP1896404B1 (en) *	2005-06-27	2014-09-17	Nabriva Therapeutics AG	Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
GB0515995D0 (en)	2005-08-03	2005-09-07	Sandoz Ag	Organic compounds
EP1972618A1 (en) *	2007-03-20	2008-09-24	Nabriva Therapeutics AG	Pleuromutilin derivatives for the treatment of diseases mediated by microbes
EP2159220A1 (en) *	2008-09-02	2010-03-03	Nabriva Therapeutics AG	Organic compounds
WO2011002776A1 (en) *	2009-06-29	2011-01-06	Nitric Biotherapeutics, Inc.	Pharmaceutical formulations for iontophoretic delivery of an immunomodulator
EP2399904A1 (en)	2010-05-26	2011-12-28	Nabriva Therapeutics AG	Process for the preparation of pleuromutilins
CN103204787B (zh) *	2012-01-17	2014-10-01	北京艾百诺科技有限公司	含有取代方酸的乙酸妙林酯及其应用
CN103626693B (zh) *	2012-08-28	2016-09-14	中国科学院上海药物研究所	一类截短侧耳素衍生物、其药物组合物及其合成方法与用途
RU2675847C2 (ru) *	2013-05-28	2018-12-25	Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми	Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций
TWI762573B (zh) *	2017-02-10	2022-05-01	奧地利商納畢瓦治療有限責任公司	截短側耳素之純化

2016
- 2016-06-14 PT PT167292580T patent/PT3310331T/pt unknown
- 2016-06-14 AU AU2016278774A patent/AU2016278774C1/en active Active
- 2016-06-14 HU HUE16729258A patent/HUE053024T2/hu unknown
- 2016-06-14 PL PL16729258T patent/PL3310331T3/pl unknown
- 2016-06-14 JP JP2018517478A patent/JP6818019B2/ja active Active
- 2016-06-14 KR KR1020177037107A patent/KR102656841B1/ko active Active
- 2016-06-14 CN CN201680034551.7A patent/CN107810000B/zh active Active
- 2016-06-14 SI SI201631026T patent/SI3310331T1/sl unknown
- 2016-06-14 RS RS20210014A patent/RS61327B1/sr unknown
- 2016-06-14 LT LTEP16729258.0T patent/LT3310331T/lt unknown
- 2016-06-14 CA CA2989372A patent/CA2989372C/en active Active
- 2016-06-14 HR HRP20210010TT patent/HRP20210010T1/hr unknown
- 2016-06-14 UA UAA201712491A patent/UA121240C2/uk unknown
- 2016-06-14 MX MX2017015812A patent/MX383032B/es unknown
- 2016-06-14 EP EP16729258.0A patent/EP3310331B1/en active Active
- 2016-06-14 ES ES16729258T patent/ES2843723T3/es active Active
- 2016-06-14 US US15/736,865 patent/US12121582B2/en active Active
- 2016-06-14 DK DK16729258.0T patent/DK3310331T3/da active
- 2016-06-14 BR BR112017026904-0A patent/BR112017026904B1/pt active IP Right Grant
- 2016-06-14 WO PCT/EP2016/063609 patent/WO2016202788A1/en not_active Ceased
- 2016-06-14 EA EA201890075A patent/EA033988B1/ru unknown
- 2016-06-15 TW TW105118788A patent/TWI718158B/zh not_active IP Right Cessation
2017
- 2017-11-24 ZA ZA2017/07998A patent/ZA201707998B/en unknown
- 2017-12-05 IL IL256115A patent/IL256115A/en active IP Right Grant
- 2017-12-15 PH PH12017502319A patent/PH12017502319A1/en unknown
2021
- 2021-01-13 CY CY20211100027T patent/CY1123722T1/el unknown
2024
- 2024-09-20 US US18/891,571 patent/US20250009885A1/en active Pending

Also Published As

Publication number	Publication date
KR20180030479A (ko)	2018-03-23
PL3310331T3 (pl)	2021-04-19
IL256115A (en)	2018-02-28
HRP20210010T1 (hr)	2021-03-05
AU2016278774C1 (en)	2021-11-18
WO2016202788A1 (en)	2016-12-22
UA121240C2 (uk)	2020-04-27
CN107810000A (zh)	2018-03-16
TW201716056A (zh)	2017-05-16
AU2016278774A1 (en)	2017-12-07
JP6818019B2 (ja)	2021-01-20
CA2989372A1 (en)	2016-12-22
SI3310331T1 (sl)	2021-02-26
EA033988B1 (ru)	2019-12-17
HUE053024T2 (hu)	2021-06-28
US20180360966A1 (en)	2018-12-20
US12121582B2 (en)	2024-10-22
KR102656841B1 (ko)	2024-04-12
US20250009885A1 (en)	2025-01-09
EP3310331B1 (en)	2020-10-14
LT3310331T (lt)	2021-01-11
HK1252534A1 (zh)	2019-05-31
CA2989372C (en)	2023-10-03
DK3310331T3 (da)	2021-01-11
RS61327B1 (sr)	2021-02-26
EA201890075A1 (ru)	2018-05-31
PH12017502319A1 (en)	2018-06-25
BR112017026904A2 (pt)	2018-08-14
JP2018517777A (ja)	2018-07-05
MX2017015812A (es)	2018-07-06
ES2843723T3 (es)	2021-07-20
BR112017026904B1 (pt)	2023-10-10
TWI718158B (zh)	2021-02-11
EP3310331A1 (en)	2018-04-25
CY1123722T1 (el)	2022-05-27
ZA201707998B (en)	2021-04-28
MX383032B (es)	2025-03-13
CN107810000B (zh)	2021-03-12
AU2016278774B2 (en)	2021-07-29

Publication	Publication Date	Title
IL287947A (en)	2022-01-01	Viscosity reduction of pharmaceutical preparations
SG11201706123XA (en)	2017-08-30	Pharmaceutical compositions comprising meloxicam
PT4070787T (pt)	2023-05-22	Formulações farmacêuticas
IL256491A (en)	2018-02-28	Pharmaceutical formulations
IL253570A0 (en)	2017-09-28	Pharmacy composition
IL256115A (en)	2018-02-28	Pharmaceutical formulations of injectable lapmoline
IL253177A0 (en)	2017-08-31	Pharmacy preparation
ZA201707094B (en)	2021-04-28	Pharmaceutical formulations
IL255510A (en)	2018-04-30	Pharmaceutical compositions
IL267279A (en)	2019-08-29	Pharmaceutical formulations of suvorexant
IL251559B (en)	2021-02-28	Pharmaceutical preparations of the history of aminodihydrothiazines from Amano
IL252729A0 (en)	2017-08-31	Injectable formulations of acetaminophen
GB201511246D0 (en)	2015-08-12	Pharmaceutical formulation
ZA201705329B (en)	2019-06-26	Pharmaceutical formulations of racecadotril
HRP20220610T8 (hr)	2023-03-31	Farmaceutski pripravci koji sadrže meloksikam
PL3319596T3 (pl)	2024-04-15	Farmaceutyczne kompozycje
GB201506598D0 (en)	2015-06-03	Pharmaceutical compositions